TSG Advice Partners LLC Makes New $1.48 Million Investment in AbbVie Inc. $ABBV

TSG Advice Partners LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 5,869 shares of the company’s stock, valued at approximately $1,477,000.

Other large investors have also recently added to or reduced their stakes in the company. Burk Holdings LLC bought a new position in shares of AbbVie in the 2nd quarter valued at about $30,000. Marquette Asset Management LLC raised its holdings in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the period. IMG Wealth Management Inc. raised its holdings in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after purchasing an additional 153 shares during the period. Principia Wealth Advisory LLC raised its holdings in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Tacita Capital Inc acquired a new stake in AbbVie in the 2nd quarter valued at about $42,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Expanded migraine partnership: AbbVie and Brise Pharmaceuticals announced a global license agreement to advance next-generation migraine treatments, potentially worth up to $757 million. The deal adds another growth opportunity to AbbVie’s neuroscience pipeline. AbbVie, Brise Expand Migraine Drug Partnership
• Positive Sentiment: Positive migraine data: A Phase 3 study published in The Lancet Neurology reportedly delivered a favorable result, supporting the commercial potential of AbbVie’s migraine portfolio. AbbVie Lands Phase 3 Migraine Study Win
• Positive Sentiment: Analyst optimism increased: Cantor Fitzgerald raised its price target to $325, while RBC, Canaccord Genuity, Leerink Partners and Morgan Stanley lifted targets to $330, $338, $342 and $346, respectively. The revisions reflect confidence in AbbVie’s immunology transition and raised outlook. Analysts Increase Forecasts on AbbVie
• Positive Sentiment: Strong operating performance: Third-quarter revenue rose 10.3% to $17.4 billion, while adjusted EPS of $3.82 exceeded expectations. Skyrizi, Rinvoq and neuroscience products are offsetting Humira’s decline, and management raised its 2026 revenue and earnings outlook. ABBV Q3 Earnings Call Highlights
• Positive Sentiment: Dividend increase: AbbVie raised its quarterly dividend 5.2% to $1.82 per share, signaling confidence in cash flow and reinforcing the stock’s income appeal.
• Neutral Sentiment: Legal win: AbbVie prevailed in a lawsuit against the U.S. Department of Health and Human Services concerning drug-price controls, potentially reducing near-term regulatory uncertainty. AbbVie Wins Drug Price Control Lawsuit
• Negative Sentiment: Transition and valuation risks remain: Humira sales continue to decline, leaving investors dependent on Skyrizi, Rinvoq and pipeline launches to sustain growth. After a sharp rally, ABBV’s elevated valuation and proximity to its 52-week high may also be prompting profit-taking despite the positive updates. AbbVie’s Humira Era Is Fading

AbbVie Price Performance

NYSE:ABBV opened at $288.66 on Tuesday. AbbVie Inc. has a one year low of $190.75 and a one year high of $298.74. The company has a market cap of $509.99 billion, a P/E ratio of 49.68, a P/E/G ratio of 1.31 and a beta of 0.24. The firm’s fifty day moving average price is $269.81 and its two-hundred day moving average price is $237.57.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.86 earnings per share. As a group, equities research analysts expect that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $1.82 dividend. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is currently 119.10%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ABBV shares. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Cantor Fitzgerald boosted their price target on AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research report on Monday. Royal Bank Of Canada upped their price objective on AbbVie from $280.00 to $330.00 and gave the company an “outperform” rating in a research note on Monday. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Finally, Morgan Stanley raised their price objective on AbbVie from $310.00 to $346.00 and gave the company an “overweight” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.67.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.